Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

TGF- 1ÀÌ Àü¸³¼± ¼¼Æ÷Áõ½Ä¿¡ ¹ÌÄ¡´Â ¿µÇâ Effect of Transforming Growth Factor 1 ib Orikuferatuib if Proliferation of Prostatic Cells

´ëÇѺñ´¢±â°úÇÐȸÁö 1993³â 34±Ç 4È£ p.770 ~ 777
±èÇöÁÖ, ·ù±Ù°©, ¾ÈÇÑÁ¾,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇöÁÖ (  ) 
¿ï»ê´ëÇб³

·ù±Ù°© (  ) 
¿ï»ê´ëÇб³
¾ÈÇÑÁ¾ (  ) 
¿ï»ê´ëÇб³

Abstract


Transforming growth factor ¥â1, a prototypical autocrine growth factor, exhibits such a remarkable diversity of biological activity that may stimulate or inhibit cellular proliferation and stimulate extracellular matrix formation depending on the
cell
type. We evaluated the effect of TGF-¥â1 on proliferation of the human prostatic epithelial cell and fibroblast. Epithelial cells were released from tissues by collagen digestion, and primary and subcultured cells were grown in PFMR-4A medium
supplemented with epidermal growth factor, phosphoethanolamine, cholera toxin, selenium, insulin, hydrocortisone, and bovine pituitary extract. Prostate-derived fibroblasts were cultured using RPMI 1640 medium with 10% fetal bovine serum.
Verification
of prostatic epithelial cells was accomplished by indirect immunofluorescence detection of prostate specific antigen, cytokeratin, and prostate-derived fibroblast was confirmed by immunofluorescence detection of vimentin. Proliferation assay was
performed using 3H-thymidine assay. Time and dose dependant inhibitory effects of TGF-¥â1 on proliferation of prostatic epithelial cells were noted (86¡¾6%, at 0.1ng/ml and 21¡¾3% at 10ng/ml after 96hr exposure), while TGF-¡¾1 at a high
concentration
stimulated the proliferation of prostate-derived fibroblasts (125¡¾11% at 1ng/ml after 48hr exposure, 118¡¾10% at 1ng/ml after 96hr exposure). However in the absence of fetal bovine serum, TGF-¥â1, at, a physiologic range of 0.01ng/ml showed
inhibitory
effect on proliferation of prostate-derived fibroblasts. These data show that TGF-¥â1, a growth modulating cytokine, regulates growth of prostatic epithelial cells and prostate-derived fibrblast in the different way.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS